

# Angelos Koutras

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6299369/publications.pdf>

Version: 2024-02-01

46  
papers

606  
citations

623734

14  
h-index

677142

22  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1419  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial. <i>British Journal of Cancer</i> , 2022, 127, 695-703.	6.4	2
2	Genetic Variation in the Vascular Endothelial Growth Factor (VEGFA) Gene at rs13207351 Is Associated with Overall Survival of Patients with Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 1163.	3.7	4
3	Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer. <i>Anticancer Research</i> , 2021, 41, 1793-1802.	1.1	2
4	mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumab. <i>Oncology Letters</i> , 2021, 23, 23.	1.8	1
5	Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-based Regimens. <i>Cancer Research and Treatment</i> , 2021, . .	3.0	1
6	The Role of CXCL13 and CXCL9 in Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e36-e53.	2.4	29
7	Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial. <i>British Journal of Cancer</i> , 2020, 123, 355-361.	6.4	8
8	Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1549-1564.	4.2	19
9	Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. <i>Oncotarget</i> , 2020, 11, 1-14.	1.8	1
10	Improvement of Chemotherapy Solutions Production Procedure in a Hospital Central Chemotherapy Preparation Unit: A Systematic Risk Assessment to Prevent Avoidable Harm in Cancer Patients. <i>Clinical Medicine Insights: Oncology</i> , 2019, 13, 117955491985293.	1.3	10
11	Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab. <i>ESMO Open</i> , 2019, 4, e000441.	4.5	3
12	Expression of Immune System-Related Membrane Receptors CD40, RANK, BAFFR and LT1 <sup>2</sup> R is Associated with Clinical Outcome of Operated Non-Small-Cell Lung Cancer Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 741.	2.4	10
13	Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 195-206.	2.0	13
14	Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab. <i>Translational Oncology</i> , 2019, 12, 739-748.	3.7	5
15	Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome. <i>Clinical Breast Cancer</i> , 2019, 19, 113-125.e4.	2.4	8
16	The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 411-419.	2.2	4
17	Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe. <i>International Journal of Cancer</i> , 2018, 142, 66-80.	5.1	13
18	Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. <i>Clinical Breast Cancer</i> , 2018, 18, 53-62.e3.	2.4	8

#	ARTICLE	IF	CITATIONS
19	Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study. PLoS ONE, 2018, 13, e0207707.	2.5	4
20	Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. Cancer Medicine, 2018, 7, 5066-5082.	2.8	12
21	Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab. Cancer Genomics and Proteomics, 2018, 15, 461-471.	2.0	13
22	Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial. PLoS ONE, 2018, 13, e0200302.	2.5	21
23	Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. Journal of Translational Medicine, 2017, 15, 30.	4.4	14
24	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. Translational Oncology, 2017, 10, 589-598.	3.7	17
25	Protein expression patterns of cell cycle regulators in operable breast cancer. PLoS ONE, 2017, 12, e0180489.	2.5	14
26	The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy. Anticancer Research, 2017, 37, 2947-2957.	1.1	9
27	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. Oncotarget, 2016, 7, 32731-32753.	1.8	30
28	Identification of a seasonal pattern to brain metastases. Neuropsychiatric Disease and Treatment, 2016, 12, 609.	2.2	0
29	Statins and risk of breast cancer recurrence. Breast Cancer: Targets and Therapy, 2016, Volume 8, 199-205.	1.8	26
30	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. Breast Cancer Research and Treatment, 2016, 158, 307-321.	2.5	16
31	Long-term disease stabilization following treatment with erlotinib in heavily pretreated patients with wild-type epidermal growth factor receptor non-small-cell lung carcinoma: Two case reports. Molecular and Clinical Oncology, 2016, 5, 803-806.	1.0	0
32	MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. Journal of Translational Medicine, 2016, 14, 136.	4.4	25
33	Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia. Molecular and Clinical Oncology, 2016, 4, 211-220.	1.0	11
34	Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. Clinical Breast Cancer, 2016, 16, 291-298.e3.	2.4	17
35	Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. PLoS ONE, 2016, 11, e0164013.	2.5	4
36	Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget, 2016, 7, 5074-5087.	1.8	54

#	ARTICLE	IF	CITATIONS
37	Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. <i>Journal of Translational Medicine</i> , 2015, 13, 171.	4.4	15
38	Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. <i>PLoS ONE</i> , 2015, 10, e0140293.	2.5	29
39	Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer. <i>Pharmacogenomics</i> , 2015, 16, 79-94.	1.3	27
40	p85 Protein Expression is Associated with Poor Survival in HER2-Positive Patients with Advanced Breast Cancer Treated with Trastuzumab. <i>Pathology and Oncology Research</i> , 2015, 21, 273-282.	1.9	9
41	Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study. <i>Histology and Histopathology</i> , 2015, 30, 1129-41.	0.7	2
42	The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. <i>Breast</i> , 2014, 23, 234-243.	2.2	26
43	Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 330-338.	2.4	10
44	alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies. <i>BMC Clinical Pathology</i> , 2014, 14, 28.	1.8	13
45	Differential Expression of the Insulin-Like Growth Factor Receptor among Early Breast Cancer Subtypes. <i>PLoS ONE</i> , 2014, 9, e91407.	2.5	15
46	Antiproliferative effect of exemestane in lung cancer cells. <i>Molecular Cancer</i> , 2009, 8, 109.	19.2	32